Ntalouka Foteini, Tsirivakou Athina
Department of Research and Development, Whisper P.C., Athens, Greece.
Front Pain Res (Lausanne). 2023 Mar 1;4:1114428. doi: 10.3389/fpain.2023.1114428. eCollection 2023.
Pain due to chronic conditions is a frequent and insufficiently addressed problem. Current drug options for pain management (either in cases of chronic inflammatory conditions or neuropathy) do not adequately treat pain. Moreover, they are associated with important adverse events in long term use. Luteolin is a flavonoid widely present in the plant kingdom and its sources have been assembled in a comprehensive list of this paper. Luteolin has shown in several research studies a range of pharmacological properties; anti-inflammatory, antioxidant, neuroprotective, and analgesic. In this article, we summarize the effects and potential benefits from introducing luteolin as an adjuvant agent in established protocols for pain management. We review the most indicative and evidence of how luteolin can target the molecular pathways involved in pathogenesis of chronic inflammatory and neuropathic pain. The data reviewed strongly support luteolin's promising benefits in pain management and raise the need for further clinical trials that can establish its role in clinical practice.
慢性病引起的疼痛是一个常见且未得到充分解决的问题。目前用于疼痛管理的药物选择(无论是慢性炎症性疾病还是神经病变的情况)都不能充分治疗疼痛。此外,长期使用这些药物会引发重要的不良事件。木犀草素是一种广泛存在于植物界的黄酮类化合物,其来源已汇总在本文的一份综合列表中。在多项研究中,木犀草素已显示出一系列药理特性:抗炎、抗氧化、神经保护和镇痛。在本文中,我们总结了在既定的疼痛管理方案中引入木犀草素作为辅助药物的效果和潜在益处。我们回顾了最具指示性的内容以及木犀草素如何靶向参与慢性炎症性和神经性疼痛发病机制的分子途径的证据。所审查的数据有力地支持了木犀草素在疼痛管理方面的潜在益处,并提出需要进一步开展临床试验以确定其在临床实践中的作用。